Indegene Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.7 pts more than Nifty Smallcap 250 and 5.1 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indegene Limited reported its Q1 FY26 results on July 31, 2025. Consolidated revenue from operations grew to ₹7,608 million, up from ₹6,765 million in the same quarter last year (~12.5% YoY growth). Profit after tax jumped to ₹1,164 million from ₹877 million, a strong ~32.7% YoY increase, with basic EPS rising to ₹4.86 from ₹3.79. The Enterprise Commercial Solutions segment was the largest contributor at ₹4,453 million in revenue, followed by Enterprise Medical Solutions at ₹2,132 million. The Board also approved allotment of shares under the ESOP 2020 Plan. A final dividend of ₹2 per share for FY25 was paid on June 30, 2025. Auditor Deloitte Haskins & Sells issued an unmodified (unqualified) review opinion on the results.
Positive for shareholders — strong profit growth (~33% YoY) significantly outpaced revenue growth, indicating healthy margin expansion and operational efficiency. The new auditor (Deloitte) replacing the predecessor for current period review and the ESOP allotment are routine governance signals and not concerning.